Ron Cooper has served as our CEO and a member of our Board of Directors since July 2024. Previously, Mr. Cooper was president and chief executive officer of Albireo Pharma, a fully integrated global commercial biopharmaceutical company that was acquired by Ipsen for up to $1.2 billion in March 2023. While at Albireo Pharma, Mr. Cooper took the company public; created a new corporate strategy to focus development on building a rare pediatric company while monetizing other pipeline assets; guided Bylvay® through three Phase III programs, regulatory approvals and a global commercial launch; raised >$ 850 million of capital with approximately 50% non-dilutive. Earlier in his career, Mr. Cooper spent nearly 30 years at Bristol-Myers Squibb (BMS) in roles of increasing responsibility in sales, marketing and general management, most recently serving as President, Europe. While at BMS, he played a leadership role in several successful product launches, including Abilify®, Avapro®, Atripla®, Eliquis®, Orencia®, Pravachol®, Plavix®, Reyataz®, Sustiva®, Sprycel® and Yervoy®. Mr. Cooper currently serves as the Chairman of the Board for C4 Therapeutics, member of the Board of Directors of Generation Bio, and he has previously served on the Boards of Directors of Genocea Biosciences and Albireo Pharma. He is a graduate of St. Francis Xavier University in Canada.

• 

  Chief Executive Officer (CEO) in enGene

  Mainstreaming Gene Therapy